These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 33009446)
21. An X-linked NDI mutation reveals a requirement for cell surface V2R expression. Sadeghi HM; Innamorati G; Birnbaumer M Mol Endocrinol; 1997 Jun; 11(6):706-13. PubMed ID: 9171234 [TBL] [Abstract][Full Text] [Related]
22. V2 vasopressin receptor mutations. Makita N; Manaka K; Sato J; Iiri T Vitam Horm; 2020; 113():79-99. PubMed ID: 32138955 [TBL] [Abstract][Full Text] [Related]
23. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones. Szalai L; Sziráki A; Erdélyi LS; Kovács KB; Tóth M; Tóth AD; Turu G; Bonnet D; Mouillac B; Hunyady L; Balla A Front Pharmacol; 2022; 13():811836. PubMed ID: 35153784 [TBL] [Abstract][Full Text] [Related]
24. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Robben JH; Sze M; Knoers NV; Deen PM Mol Biol Cell; 2006 Jan; 17(1):379-86. PubMed ID: 16267275 [TBL] [Abstract][Full Text] [Related]
25. Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Bichet DG; Turner M; Morin D Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088 [TBL] [Abstract][Full Text] [Related]
26. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Rochdi MD; Vargas GA; Carpentier E; Oligny-Longpré G; Chen S; Kovoor A; Gitelman SE; Rosenthal SM; von Zastrow M; Bouvier M Mol Pharmacol; 2010 May; 77(5):836-45. PubMed ID: 20159941 [TBL] [Abstract][Full Text] [Related]
27. Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. Ala Y; Morin D; Mouillac B; Sabatier N; Vargas R; Cotte N; Déchaux M; Antignac C; Arthus MF; Lonergan M; Turner MS; Balestre MN; Alonso G; Hibert M; Barberis C; Hendy GN; Bichet DG; Jard S J Am Soc Nephrol; 1998 Oct; 9(10):1861-72. PubMed ID: 9773787 [TBL] [Abstract][Full Text] [Related]
28. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus. Faerch M; Christensen JH; Rittig S; Johansson JO; Gregersen N; de Zegher F; Corydon TJ Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1518-25. PubMed ID: 19812297 [TBL] [Abstract][Full Text] [Related]
29. Novel signalling pathways in nephrogenic syndrome of inappropriate antidiuresis: functional implication of site-specific AQP2 phosphorylation. Venneri M; Vezzi V; Di Mise A; Ranieri M; Centrone M; Tamma G; Nejsum LN; Valenti G J Physiol; 2024 Jul; 602(13):3169-3189. PubMed ID: 36823952 [TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature. Neocleous V; Skordis N; Shammas C; Efstathiou E; Mastroyiannopoulos NP; Phylactou LA Metabolism; 2012 Jul; 61(7):922-30. PubMed ID: 22386940 [TBL] [Abstract][Full Text] [Related]
31. Demonstration of the functional impact of vasopressin signaling in the thick ascending limb by a targeted transgenic rat approach. Mutig K; Borowski T; Boldt C; Borschewski A; Paliege A; Popova E; Bader M; Bachmann S Am J Physiol Renal Physiol; 2016 Aug; 311(2):F411-23. PubMed ID: 27306979 [TBL] [Abstract][Full Text] [Related]
32. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration. Miyakoshi M; Kamoi K; Uchida S; Sasaki S Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855 [TBL] [Abstract][Full Text] [Related]
33. Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells. Andersen-Beckh B; Dehe M; Schülein R; Wiesner B; Rutz C; Liebenhoff U; Rosenthal W; Oksche A Kidney Int; 1999 Aug; 56(2):517-27. PubMed ID: 10432391 [TBL] [Abstract][Full Text] [Related]
34. Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus. Böselt I; Tramma D; Kalamitsou S; Niemeyer T; Nykänen P; Gräf KJ; Krude H; Marenzi KS; Di Candia S; Schöneberg T; Schulz A Nephrol Dial Transplant; 2012 Apr; 27(4):1521-8. PubMed ID: 21917732 [TBL] [Abstract][Full Text] [Related]
35. V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology. Erdélyi LS; Hunyady L; Balla A Front Endocrinol (Lausanne); 2023; 14():1173601. PubMed ID: 37293495 [TBL] [Abstract][Full Text] [Related]
36. A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers. Schernthaner-Reiter MH; Adams D; Trivellin G; Ramnitz MS; Raygada M; Golas G; Faucz FR; Nilsson O; Nella AA; Dileepan K; Lodish M; Lee P; Tifft C; Markello T; Gahl W; Stratakis CA Eur J Pediatr; 2016 May; 175(5):727-33. PubMed ID: 26795631 [TBL] [Abstract][Full Text] [Related]
37. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus. Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106 [TBL] [Abstract][Full Text] [Related]
38. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Robben JH; Knoers NV; Deen PM Am J Physiol Renal Physiol; 2006 Aug; 291(2):F257-70. PubMed ID: 16825342 [TBL] [Abstract][Full Text] [Related]